The global dermatology market size is calculated at USD 1.70 billion in 2024, grew to USD 1.82 billion in 2025, and is projected to reach around USD 3.59 billion by 2034. The market is poised to grow at a CAGR of 7.03% between 2024 and 2034. The North America dermatology market size is predicted to increase from USD 640 million in 2024 and is estimated to grow at the fastest CAGR of 7.18% during the forecast year.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Dermatology Market
5.1. COVID-19 Landscape: Dermatology Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Dermatology Market, By Type
8.1. Dermatology Market, by Type, 2024-2034
8.1.1 Medical Dermatology
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Surgical Dermatology
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Pediatric Dermatology
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Cosmetic Dermatology
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Cutaneous Lymphoma
8.1.5.1. Market Revenue and Forecast (2021-2034)
8.1.6. Dermatoimmunology
8.1.6.1. Market Revenue and Forecast (2021-2034)
8.1.7. Others
8.1.7.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Dermatology Market, By Application
9.1. Dermatology Market, by Application, 2024-2034
9.1.1. Acne
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Dermatitis
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Psoriasis
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Skin Cancer
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Rosacea
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. Alopecia
9.1.6.1. Market Revenue and Forecast (2021-2034)
9.1.7. Others
9.1.7.1. Market Revenue and Forecast (2021-2034)
Chapter 10. Global Dermatology Market, By End-Use
10.1. Dermatology Market, by End-Use, 2024-2034
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Skin Clinics
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2021-2034)
Chapter 11. Global Dermatology Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Type (2021-2034)
11.1.2. Market Revenue and Forecast, by Application (2021-2034)
11.1.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Type (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.1.4.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Type (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.1.5.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Type (2021-2034)
11.2.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Type (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.4.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Type (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.5.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Type (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.6.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Type (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.7.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Type (2021-2034)
11.3.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Type (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.4.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Type (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.5.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Type (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.6.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Type (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.7.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Type (2021-2034)
11.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Type (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.4.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Type (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.5.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Type (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.6.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Type (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.7.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Type (2021-2034)
11.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.5.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Type (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.5.4.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Type (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.5.5.3. Market Revenue and Forecast, by End-Use (2021-2034)
Chapter 12. Company Profiles
12.1. AbbVie Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Pfizer Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. GSK plc
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. LEO Pharma A/S
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Sun Pharmaceutical Industries Ltd
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Galderma S.A.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Amgen Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. DermBiont, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Johnson & Johnson Services Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Roivant Sciences Ltd
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample